Q1 2020 Earnings Estimate for Miragen Therapeutics Inc (MGEN) Issued By Wedbush

Share on StockTwits

Miragen Therapeutics Inc (NASDAQ:MGEN) – Investment analysts at Wedbush issued their Q1 2020 EPS estimates for shares of Miragen Therapeutics in a research note issued on Monday, March 18th. Wedbush analyst L. Moussatos expects that the medical research company will earn ($0.45) per share for the quarter. Wedbush currently has a “Outperform” rating and a $24.00 target price on the stock. Wedbush also issued estimates for Miragen Therapeutics’ Q2 2020 earnings at ($0.45) EPS, Q3 2020 earnings at ($0.46) EPS and Q4 2020 earnings at ($0.47) EPS.

Other research analysts have also recently issued reports about the company. Zacks Investment Research raised Miragen Therapeutics from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a report on Friday, January 4th. B. Riley initiated coverage on Miragen Therapeutics in a report on Monday, December 31st. They issued a “buy” rating and a $18.50 price target for the company. Finally, Robert W. Baird initiated coverage on Miragen Therapeutics in a report on Friday, January 4th. They issued an “outperform” rating for the company. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $15.63.

Miragen Therapeutics stock opened at $3.41 on Wednesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.71 and a quick ratio of 9.71. Miragen Therapeutics has a 12-month low of $2.20 and a 12-month high of $8.20. The stock has a market capitalization of $100.18 million, a P/E ratio of -3.10 and a beta of 1.21.

Miragen Therapeutics (NASDAQ:MGEN) last released its quarterly earnings results on Wednesday, March 13th. The medical research company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.02). Miragen Therapeutics had a negative net margin of 389.97% and a negative return on equity of 51.82%. The business had revenue of $0.48 million during the quarter, compared to the consensus estimate of $1.54 million.

A number of hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP increased its position in Miragen Therapeutics by 2.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 216,866 shares of the medical research company’s stock worth $657,000 after purchasing an additional 4,404 shares during the period. SG Americas Securities LLC increased its position in Miragen Therapeutics by 7.2% in the fourth quarter. SG Americas Securities LLC now owns 99,324 shares of the medical research company’s stock worth $301,000 after purchasing an additional 6,662 shares during the period. Bank of America Corp DE increased its position in Miragen Therapeutics by 35.9% in the fourth quarter. Bank of America Corp DE now owns 33,116 shares of the medical research company’s stock worth $100,000 after purchasing an additional 8,756 shares during the period. Rhumbline Advisers increased its position in Miragen Therapeutics by 51.4% in the fourth quarter. Rhumbline Advisers now owns 33,350 shares of the medical research company’s stock worth $101,000 after purchasing an additional 11,321 shares during the period. Finally, Geode Capital Management LLC increased its position in Miragen Therapeutics by 5.3% in the fourth quarter. Geode Capital Management LLC now owns 230,127 shares of the medical research company’s stock worth $697,000 after purchasing an additional 11,541 shares during the period. Hedge funds and other institutional investors own 47.59% of the company’s stock.

About Miragen Therapeutics

Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan.

See Also: Retained Earnings

Earnings History and Estimates for Miragen Therapeutics (NASDAQ:MGEN)

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Twilio Inc  General Counsel Sells $3,074,866.60 in Stock
Twilio Inc General Counsel Sells $3,074,866.60 in Stock
Lam Research  Updates Q4 2019 Earnings Guidance
Lam Research Updates Q4 2019 Earnings Guidance
Zacks: Brokerages Anticipate Reata Pharmaceuticals Inc  to Announce -$0.97 Earnings Per Share
Zacks: Brokerages Anticipate Reata Pharmaceuticals Inc to Announce -$0.97 Earnings Per Share
NPER  Market Capitalization Achieves $222,981.00
NPER Market Capitalization Achieves $222,981.00
Centurylink  Hits New 12-Month Low at $11.51
Centurylink Hits New 12-Month Low at $11.51
Core Laboratories  Updates Q2 2019 Earnings Guidance
Core Laboratories Updates Q2 2019 Earnings Guidance


© 2006-2019 Ticker Report